FDA’s plan to boost biosimilar drugs could stall at the patent office

FDA’s plan to boost biosimilar drugs could stall at the patent office

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry officials say.